# Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.

> **NCT01268774** · — · COMPLETED · sponsor: **LEO Pharma** · enrollment: 529 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01268774
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-07
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2013-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268774, "Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01268774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*